{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:29:24Z","timestamp":1793212164783,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010780","name":"Celltrion Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cgh.2025.04.028","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T11:53:58Z","timestamp":1747655638000},"page":"2597-2606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission"],"prefix":"10.1016","volume":"23","author":[{"given":"Nicolas","family":"Mathieu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5158-2321","authenticated-orcid":false,"given":"Marianne","family":"Hup\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Heluwaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"H\u00e9buterne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Chupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vered","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bouguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucine","family":"Vuitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Gornet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Montuclard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Nancey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cadiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Gilletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"de Maissin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Altwegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Chanteloup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurianne","family":"Plastaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ah Soune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bourreille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Stefanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Seksik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Uzzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Andrau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9a","family":"Rouillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Arondel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Buisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassirou","family":"Mboup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4753-6676","authenticated-orcid":false,"given":"David","family":"Laharie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2025.04.028_bib1","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2025.04.028_bib2","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2025.04.028_bib3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.04.028_bib4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11096-022-01509-1","article-title":"Comparative efficacy of advanced treatments in biologic-na\u00efve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis","volume":"45","author":"Lu","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.cgh.2025.04.028_bib5","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2025.04.028_bib6","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"8","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.04.028_bib7","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/ibd.21888","article-title":"Systematic assessment of factors influencing preferences of Crohn\u2019s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL)","volume":"18","author":"Vavricka","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.04.028_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40271-014-0075-y","article-title":"Intravenous versus subcutaneous drug administration. which do patients prefer? A systematic review","volume":"8","author":"Stoner","year":"2015","journal-title":"Patient"},{"key":"10.1016\/j.cgh.2025.04.028_bib9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/ibd\/izac119","article-title":"Comparative acceptability of therapeutic maintenance regimens in patients with inflammatory bowel disease: results from the nationwide ACCEPT2 study","volume":"29","author":"Buisson","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.04.028_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14341","article-title":"Comparing cost of intravenous infusion and subcutaneous biologics in COVID-19 pandemic care pathways for rheumatoid arthritis and inflammatory bowel disease: a brief UK stakeholder survey","volume":"75","author":"Heald","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.cgh.2025.04.028_bib11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/00365521.2023.2285229","article-title":"Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses","volume":"59","author":"Harno-Tasihin","year":"2024","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.04.028_bib12","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT-P13) as maintenance therapy for inflammatory bowel disease: 2 randomized phase 3 trials","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.04.028_bib13","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.04.028_bib14","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT-P13]: a multicentre cohort study","volume":"16","author":"Smith","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.04.028_bib15","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.3390\/biomedicines10092130","article-title":"Subcutaneous infliximab [CT-P13], a true biologic 2.0. Real clinical practice multicentre study","volume":"10","author":"Huguet","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.cgh.2025.04.028_bib16","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/apt.17822","article-title":"Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: the REMSWITCH-LT study","volume":"59","author":"Buisson","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2025.04.028_bib17","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.04.028_bib18","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.04.028_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.dld.2024.09.015","article-title":"Persistence of subcutaneous versus intravenous infliximab in a real-life cohort: a propensity-score matched comparative analysis","volume":"57","author":"Bothorel","year":"2025","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2025.04.028_bib20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ecco-jcc\/jjad188","article-title":"Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease","volume":"18","author":"Roblin","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.04.028_bib21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40261-023-01252-z","article-title":"Subcutaneous infliximab monotherapy versus combination therapy with immunosuppressants in inflammatory bowel disease: a post hoc analysis of a randomised clinical trial","volume":"43","author":"D\u2019Haens","year":"2023","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cgh.2025.04.028_bib22","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/ecco-jcc\/jjaa100","article-title":"VALIDation of the IBD-disk instrument for assessing disability in inflammatory bowel diseases in a French cohort: the VALIDate study","volume":"14","author":"Le Berre","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.04.028_bib23","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/ecco-jcc\/jjaa244","article-title":"The IBD-disk is a reliable tool to assess the daily-life burden of patients with inflammatory bowel disease","volume":"15","author":"Tadbiri","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.04.028_bib24","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/ecco-jcc\/jjae059","article-title":"Intravenous versus subcutaneous infliximab in inflammatory bowel disease: a systematic review and meta-analysis","volume":"18","author":"Chetwood","year":"2024","journal-title":"J Crohns Colitis"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525004252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525004252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:15:58Z","timestamp":1783628158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356525004252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1542356525004252"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2025.04.028","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2025.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the AGA Institute","name":"copyright","label":"Copyright"}]}}